Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 12

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 12
---
div>

Share Exchange Agreement

On July 23, 2024, we consummated the share exchange
transaction (the “Share Exchange”) contemplated by the Stock Exchange Agreement, dated November 14, 2023 (the “Share
Exchange Agreement”), by and among the Company, LipoVation Ltd., a company organized under the laws of the State of Israel (“LipoVation”),
and all shareholders of LipoVation (the “LipoVation Shareholders”). As a result of the consummation of the Share Exchange,
LipoVation became a wholly owned subsidiary of the Company. At such date, the shareholders of LipoVation contributed all of their shareholdings
in LipoVation in exchange for 23,171,642 shares of the Company’s Common Stock (the “Exchange Shares”) with each LipoVation
Shareholder receiving a pro rata portion of the Exchange Shares based on their ownership in LipoVation. The Exchange Shares represented
approximately 40% of the issued and outstanding shares of the Company’s Common Stock immediately upon the closing of the Share
Exchange.

As a result of the Share Exchange, the Company
acquired the business of LipoVation, which became the primary business of the Company. Through LipoVation, the Company is dedicated to
developing innovative nano-medicines to deliver advanced treatment solutions for diseases with limited or no effective medical options.
Pursuant to the license and research agreements with Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.
(“Yissum”), executed on November 24, 2022, as amended on October 25, 2023 (the “Yissum License Agreements”),
LipoVation has exclusive license rights to develop and market a novel technology related to Nano-Liposomal Particles (NLP)-based medicines
including: (i) novel formulation of a potent antibiotic which shows promise in combating several life-threatening antibiotic-resistant
bacteria which currently have no available treatment, (ii) potent adjunct to improve cancer treatment outcomes and (iii) novel immunization
approach based on Liposomal Protein-Loaded Technology (LPLT).

The Share Exchange and the Conversion are intended
to be treated as a tax-free reorganization under Section 368(a)(1)(F) of the Internal Revenue Code of 1986, as amended.

Prior to the closing of the Share Exchange, the
Company had been developing clinical decision-making